Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus methotrexate versus methotrexate alone in active rheumatoid arthritis
2005-002392-32Phase 3Terminated
- Sponsor
- Roche
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by Roche. Primary endpoint: ACR20 response at week 24. Started Sep 2005; status: terminated.
02
Drugs
rituximabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-002392-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002392-32.